Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
SUDEEPPHRM •NSE
Sudeep Pharma
₹742.1567.45 (10.00%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events
Performance
Today’s low
680.90
Today’s high
742.15
52 week low
524.05
52 week high
795.00
Open price
697.00
Previous close
674.70
Live volume
8,53,050
Lower circuit
667.95
Upper circuit
816.35
Fundamentals
Market Cap
₹8,377Cr
ROE
19.57%
P/E Ratio(TTM)
48.07
EPS(TTM)
15.43
P/B Ratio
9.48
Dividend Yield
0.00%
Industry P/E
34.30
Book Value
78.21
Debt to Equity
0.17
Face Value
1
Financial performance
MAR '26
Revenue (Cr)
₹189
+5.35%
Profit (Cr)
₹48.54
+1.76%
050100150200
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
| Revenue growth | Value |
|---|---|
| 1Y (TTM) | +17% |
| 3Y CAGR | +33% |
| Profit growth | Value |
|---|---|
| 1Y (TTM) | +10% |
| 3Y CAGR | +61% |
About
Sudeep Pharma Limited manufactures mineral-based value-added products for pharmaceutical, food, and nutraceutical industries.;
Founded in
1989
NSE symbol
SUDEEPPHRM
Shareholding Pattern
Jun '25
Nov '25
Dec '25
Mar '26
Mutual Funds Invested (4)
Livesquawk •
Sudeep Pharma targets 86,200 MT capacity by FY27 with 51,200 MT greenfield project.
Specialty ingredients to stay at 37,500 MT; 25,000 MT added for battery materials (iron phosphate).
Livesquawk •
Sudeep Pharma's Q4 EBITDA rose 39% YoY to ₹626M from ₹451M.
Q4 EBITDA margin improved to 34.3% from 28.6%, a 5.7 pts YoY increase.
Livesquawk •
Sudeep Pharma's Q3 EBITDA rose to 600M INR from 393M YoY.
EBITDA margin improved to 34.8% from 34.0% YoY.
2026
21
May
Quarterly & Annual Result
Release date
6
Feb
Quarterly Result
Release date
2025
19
Dec
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks